[
    [
        {
            "time": "2018-01-03",
            "original_text": "Large-Cap Pharma Stocks to Watch Out for This New Year",
            "features": {
                "keywords": [
                    "Large-Cap",
                    "Pharma",
                    "Stocks",
                    "Watch",
                    "New Year"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Large-Cap Pharma Stocks to Watch Out for This New Year",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "Novo Nordisk’s Xultophy, Ryzodeg, and Fiasp Could Boost Revenue Growth in 2018",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Xultophy",
                    "Ryzodeg",
                    "Fiasp",
                    "Revenue Growth",
                    "2018"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novo Nordisk’s Xultophy, Ryzodeg, and Fiasp Could Boost Revenue Growth in 2018",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "How Is Novo Nordisk’s New Generation Insulin Segment Positioned after 3Q17?",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "New Generation",
                    "Insulin",
                    "Segment",
                    "Positioned",
                    "3Q17"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "How Is Novo Nordisk’s New Generation Insulin Segment Positioned after 3Q17?",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "How Novo Nordisk Performed in 3Q17",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Performed",
                    "3Q17"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "How Novo Nordisk Performed in 3Q17",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        }
    ]
]